Mycenax Biotech Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 113.26 million compared to TWD 159.26 million a year ago. Net loss was TWD 122 million compared to TWD 172.97 million a year ago. Basic loss per share from continuing operations was TWD 0.59 compared to TWD 1.12 a year ago. Diluted loss per share from continuing operations was TWD 0.59 compared to TWD 1.12 a year ago.
For the nine months, sales was TWD 469.7 million compared to TWD 536.41 million a year ago. Net loss was TWD 530.35 million compared to TWD 271.09 million a year ago. Basic loss per share from continuing operations was TWD 2.58 compared to TWD 1.76 a year ago. Diluted loss per share from continuing operations was TWD 2.58 compared to TWD 1.76 a year ago.